Skip to main content
. 2014 Dec 12;6(4):2088–2100. doi: 10.18632/oncotarget.2992

Figure 2. TOR-KIs and HDACi cause synergistic killing of B-ALL cell lines.

Figure 2

(A) Two Ph+ B-ALL cell lines (SUP-B15 and BV173) were cultured for 48hr with titrated concentrations of MLN0128, vorinostat or both. Viability was measured by 7-AAD staining. For the combination treatment, the values represent the concentration of MLN0128 for that condition; vorinostat was present at 5 times this concentration (for example, 100 nM MLN0128 and 500 nM vorinostat). * p < 0.05; ** p < 0.01, two-way ANOVA. (B) non-Ph B-ALL cell lines Nalm-6 and Blin-1 were analyzed as in panel A. (C) SUP-B15 and BV-173 cells were treated with the HDAC inhibitor panobinostat alone or in the presence of 100 nM MLN0128. (D) SUP-B15 and Nalm-6 cells were treated with combinations of TOR-KIs and vorinostat at fixed ratios for 48hr. Cell viability was determined, and the combination index for cell killing was calculated and graphed using Calcusyn software. The dashed line indicates a combination index of 1.